Supplementary Figures 1 - 8 from Lyn Kinase Mediates Cell Motility and Tumor Growth in EGFRvIII-Expressing Head and Neck Cancer
Year: 2023
Type: supplementary-materials
Abstract: PDF file, 1038KB, S1: Dasatinib treatment decreases migration and invasion in EGFRvIII expressing HNSCC. S2:STAT3 expression in dasatinib and Lyn siRNA treated HNSCC cells. S3: Dasatinib inhibits tumor growth in EGFRvIII expressing xenografts. S4: Increased Lyn phosphorylation in EGFRvIII-expressing HNSCC compared to vector-control cells. S5: Increase in Lyn phosphorylation in three separate clones of HNSCC cell lines Cal33. S6: Lyn siRNA specificity. S7: Knockdown of Lyn inhibits EGFRvIII-mediated HNSCC migration and invasion. S8: Knockdown of Lyn with a second siRNA confirms inhibition of EGFRvIII-mediated HNSCC migration and invasion.
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362393620